All In Biotech

Drug Trial Radar · NCT05366621

Post-fracture Medication and Mortality

The Association Between Anti-osteoporosis Medications and Lowered All Cause Mortality After Osteoporotic Fractures

Last checked: Nov 19, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

216,155

Actual

Start

Nov 1, 2020

Primary completion

Sep 30, 2021

Study completion Oct 31, 2021

Sponsor

Lead sponsor
National Cheng-Kung University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 9, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. The investigators aim to examine associations between osteoporosis medication and mortality in older adults and any type of fracture patients. The investigators also aim to discuss the pleiotropic effects of different types of anti-osteoporosis medications.

Conditions

  • Osteoporosis
  • Osteoporosis Fracture
  • Drug Therapy
  • Mortality
  • Adherence, Medication

Interventions

  • Anti-osteoporosis medicationsDrug

    Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of deaths with and without anti-osteoporotic therapy after hip fracture surgeryTime frame: 12 years
  2. Number of deaths with or without anti-osteoporosis therapy after hip or vertebral fracture surgery among older adultsTime frame: 12 years
  3. Number of deaths with and without bisphosphonates after hip or spine fracture surgeryTime frame: 12 years
  4. Number of deaths with different types of anti-osteoporosis treatments after post-fractureTime frame: 12 years
  5. Number of deaths in five leading causes of death with and without anti-osteoporosis treatment after post-fractureTime frame: 12 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Family Medicine, National Cheng Kung Univ Hosp

    Tainan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.